Hepatitis A vaccine versus immune globulin for postexposure prophylaxis

New England Journal of Medicine

Volumn 357, Issue 17, 2007, Pages 1685-1694

  Victor, John C ^a,d   Monto, Arnold S ^a   Surdina, Tatiyana Y ^b   Suleimenova, Saida Z ^b   Vaughan, Gilberto ^c   Nainan, Omana V ^c   Favorov, Michael O ^c   Margolis, Harold S ^c   Bell, Beth P ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Ministry of Health of the Republic of Kazakhstan   (Kazakhstan)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Program for Appropriate Technology in Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAY CARE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS A; HUMAN; KAZAKHSTAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 35548959176     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa070546     Document Type: Article

References (38)

1. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:RR-7:1-23.
2. World Health Organization. Global distribution of hepatitis A, B and C, 2001. Wkly Epidemiol Rec 2002;77:45-7.
3. Wasley A, Samandari T, Bell BP. Hepatitis A in the United States in the era of vaccination. JAMA 2005;294:194-201.
4. Wheeler C, Vogt TM, Armstrong GL, et al. An outbreak of hepatitis A associated with green onions. N Engl J Med 2005;353:890-7.
5. Shouval D, Ashur Y, Adler R, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 1993;11:Suppl 1:S9-S14.
6. Robertson BH, D'Hondt EH, Spelbring J, Tian H, Krawczynski K, Margolis HS. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection. J Med Virol 1994;43:249-51.
7. D'Hondt E, Purcell RH, Emerson SU, Wong DC, Shapiro M, Govindarajan S. Efficacy of an inactivated hepatitis A vaccine in pre- and postexposure conditions in marmosets. J Infect Dis 1995;171:Suppl 1:S40-S43.
8. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
9. Sagliocca L, Amoroso P, Stroffollini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomized trial. Lancet 1999;353:1136-9.
10. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. Am J Epidemiol 2006;163:204-10.
11. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000;182:12-7.
12. Blackwelder WC. Equivalence trials. In: Armitage P, Colton T, eds. Encyclopedia of biostatistics. New York: John Wiley, 1998:1367-72.
13. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62-9.
14. Clopper CJ, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
15. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998;27:1305-22.
16. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. Epidemiol Infect 2006;134:492-7.
17. Stokes J Jr, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin: preliminary note. JAMA 1945;127:144-5.
18. Brooks BF, Hsia DY-Y, Gellis SS. Family outbreaks of infectious hepatitis: prophylactic use of gamma globulin. N Engl J Med 1953;249:58-61.
19. Ashley A. Gamma globulin: effect on secondary attack rates in infectious hepatitis. N Engl J Med 1954;250:412-7.
20. Hsia DY-Y, Lonsway M Jr, Gellis SS. Gamma globulin in the prevention of infectious hepatitis: studies on the use of small doses in family outbreaks. N Engl J Med 1954;250:417-9.
21. Kluge T. Gamma-globulin in the prevention of viral hepatitis: a study on the effect of medium-size doses. Acta Med Scand 1963;174:469-77.
22. Mosley JW, Reisler DM, Brachott D, Roth D, Weiser J. Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis. Am J Epidemiol 1968;87:539-50.
23. Landrigan PJ, Huber DH, Murphy GD, Creech WB, Bryan JA. The protective efficacy of immune serum globulin in hepatitis A: a statistical approach. JAMA 1973;223:74-5.
24. Silverberg M, Neumann PZ. Infectious hepatitis: gamma-globulin prophylaxis in a community outbreak. Am J Dis Child 1970;119:117-21.
25. Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007;119(1):e12-e21.
26. National Advisory Committee on Immunization (NACI). Supplementary statement on hepatitis A vaccine (ACS-4). Can Commun Dis Rep 2000;26:12-8.
27. Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001;4:213-27.
28. Sagliocca L, Bianco E, Amoroso P, et al. Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. Vaccine 2005;23:910-4.
29. Taliani G, Gaeta GB. Hepatitis A: post-exposure prophylaxis. Vaccine 2003;21:2234-7.
30. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep (in press).
31. Sonder GJ, van Steenbergen JE, Bovee LP, Peerbooms PG, Coutinho RA, van den Hoek A. Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996-2000: an evaluation of current prevention policy. Am J Public Health 2004;94:1620-6.
32. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers: a community-wide assessment. N Engl J Med 1980;302:1222-7.
33. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infection in adults. Am J Epidemiol 1985;122:226-33.
34. Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, Purcell RH. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 1986;154:231-7.
35. Rosenblum LS, Vallarino MI, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991;164:476-82.
36. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination policy. J Infect Dis 1998;178:1579-84.
37. Skinhøj P, Mathiesen LR, Kryger P, Møller AM. Faecal excretion of hepatitis A virus in patients with symptomatic hepatitis A infection. Scand J Gastroenterol 1981;16:1057-9.
38. Rakela J, Mosley JW. Fecal excretion of hepatitis A virus in humans. J Infect Dis 1977;135:933-8.